D5980R00123
Clinical and dEmographic chaRacteristics of Patients With Frequent COPD Exacerbations and Evaluation of Therapeutic Approaches in Treatment in RussiA
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07221981/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–100 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 2024 чел. во всех странах исследования.
- Плановая дата окончания (06.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 4
Критерии включения
- Age ≥ 18 years at the time of inclusion;
- Signed and dated written informed consent in accordance with ICH-GCP and local law prior to inclusion in the study;
- Patients with diagnosed moderate-to-severe COPD (see comments below);
- ≥2 moderate or ≥1 severe COPD exacerbations in previous 52 weeks (see comments below);
- Patients have been receiving two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion.
Критерии невключения
- Current or previous treatment with triple combination (ICS/LABA/LAMA) within 52 weeks prior to inclusion;
- COPD due to documented α-1 antitrypsin deficiency;
- A diagnosis of bronchiectasis, sarcoidosis, interstitial lung diseases, or idiopathic pulmonary fibrosis, exacerbation of bronchial asthma or any acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results;
- The participation in any clinical study currently or within 52 weeks prior to inclusion.
Источник: ClinicalTrials.gov, NCT07221981 · запись обновлена в реестре 15 октября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 28
- To describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline other comorbidities of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD. — 52 weeks of retrospective data before visit 1
- To describe the baseline mean smoking index . — 52 weeks of retrospective data before visit 1
- To describe the baseline mean duration of smoking — 52 weeks of retrospective data before visit 1
- To describe the Proportion of patients with overweight — 52 weeks of retrospective data before visit 1
Цель исследования
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07221981 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.